scholarly journals Epidemiological Study of Return to Work and Mortality in Lung Cancer Survivors

2021 ◽  
Vol 19 (1) ◽  
pp. 309
Author(s):  
Zhe-Yu Yang ◽  
Ching-Huang Lai ◽  
Ching-Liang Ho ◽  
Chung-Ching Wang
Keyword(s):  
Lung Cancer ◽  
Return To Work ◽  
Cancer Survivors ◽  
Cancer Patients ◽  
Lower Risk ◽  
Research Database ◽  
Related Factors ◽  
Lung Cancer Patients ◽  
Work Related ◽  
All Cause Mortality

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide. Return to work (RTW) plays an important role for lung cancer survivors. Few studies focus solely on the relationship among possible variables and the RTW of lung cancer patients. The aim of our study was to examine sociodemographic, disease-related and work-related factors associated with RTW among lung cancer survivors in Taiwan. A total of 2206 employees who had been diagnosed with lung cancer at the Labor Insurance Database (LID), Taiwan Cancer Registry (TCR) and the National Health Insurance Research Database (NHIRD) during the period 2004–2015, were included in the study. We used the Cox proportional hazards model to investigate the associations between sociodemographic, disease-related and work-related factors on one hand and RTW on the other hand. The Kaplan–Meier method was used for analyzing the survival probability. Patients with an early cancer stage and those who underwent surgery had a higher likelihood of RTW. Factors including older age, male, higher monthly income and receipt of radiotherapy were inversely correlated with RTW. For lung cancer patients, RTW was a predictor of a lower risk of all-cause mortality in both the unadjusted and fully adjusted model. A better survival rate was found in stage III and IV lung cancer patients who had RTW. Sociodemographic and clinical-related variables had an impact on RTW among employees with lung cancer. RTW was correlated with a lower risk of all-cause mortality and better lung cancer survival. Our study showed the influence of RTW and independent confounding factors in lung cancer survivorship.

Costs, Trends, and Related Factors in Treating Lung Cancer Patients in 67 Hospitals in Guangxi, China

2017 ◽  
Vol 35 (5) ◽  
pp. 345-357 ◽  
Author(s):  
Li-Fang Zhou ◽  
Mao-Xin Zhang ◽  
Ling-Qian Kong ◽  
Gary H. Lyman ◽  
Ke Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Related Factors ◽  
Lung Cancer Patients

scholarly journals Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs

2019 ◽  
Vol 18 ◽  
pp. 153473541986949 ◽  
Author(s):  
Ming-Szu Hung ◽  
Min-Chun Chuang ◽  
Yi-Chuan Chen ◽  
Chuan-Pin Lee ◽  
Tsung-Ming Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitor ◽  
Progression Free Survival ◽  
Research Database ◽  
Lung Cancer Patients ◽  
Risk Of Death ◽  
Type 2 Dm ◽  
Egfr Tki

Background: Metformin use reportedly reduces cancer risk and improves survival in lung cancer patients. This study aimed to investigate the effect of metformin use in patients with diabetes mellitus (DM) and lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. Methods: A nationwide, population-based cohort study was conducted using the Taiwan National Health Insurance Research Database. From January 1, 2004, to December 31, 2012, a total of 373 metformin and 1260 non-metformin lung cancer cohorts with type 2 DM and EGFR-TKI treatment were studied. Results: Metformin use was significantly associated with a reduced risk of death (hazard ratio: 0.73, 95% confidence interval [CI]: 0.62-0.85, P < .001), as well as a significantly longer median progression-free survival (9.2 months, 95% CI: 8.6-11.7, vs 6.4 months, 95% CI: 5.9-7.2 months, P < .001) and median overall survival (33.4 months, 95% CI: 29.4-40.2, vs 25.4 months, 95% CI: 23.7-27.2 months, P < 0.001). Conclusions: In conclusion, metformin may potentially enhance the therapeutic effect and increase survival in type 2 DM patients with lung cancer receiving EGFR-TKI therapy.

The effect of gender on health-related quality of life and related factors in post-lobectomy lung-cancer patients

2015 ◽  
Vol 19 (3) ◽  
pp. 292-300 ◽  
Author(s):  
Nai-Wen Chang ◽  
Kuan- Chia Lin ◽  
Wen-Hu Hsu ◽  
Shih-Chun Lee ◽  
James Yi-Hsin Chan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Health Related Quality ◽  
Related Factors ◽  
Lung Cancer Patients ◽  
Related Quality ◽  
Health Related

Social inequality in survival after lung cancer: The attribution of stage at diagnosis, receipt of treatment, and comorbidity in a Danish nationwide clinical database study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6570-6570
Author(s):  
Susanne O. Dalton ◽  
Marianne Steding-Jessen ◽  
Erik Jakobsen ◽  
Joachim Schuz ◽  
Christoffer Johansen
Keyword(s):  
Lung Cancer ◽  
Social Inequality ◽  
Cancer Patients ◽  
Social Position ◽  
Living Alone ◽  
Advanced Stage ◽  
Line Treatment ◽  
Lung Cancer Patients ◽  
All Cause Mortality ◽  
Stage Lung Cancer

6570 Background: Survival after lung cancer depends on stage, treatment, and patient-specific factors as comorbidity. These factors are potentially influenced by social position (SEP). We previously reported a lower risk for advanced-stage lung cancer among persons with higher SEP and we investigate the association between SEP (education, income and cohabiting status) on receipt of 1stline treatment and overall survival in a population-based cohort of lung cancer patients in Denmark. Methods: This registry-based cohort study links data on prognostic factors and treatment from the Danish Lung Cancer Registry to individual socioeconomic information in Statistics Denmark and comorbidity from the National Hospital Discharge Registry for 13,659 persons diagnosed with lung cancer 2004-2011. Results: ORs for receipt of 1stline treatment were higher with longer education and higher income and for patients living with a partner in both men and women with low (T1-3N0M0; T0-3N1M0) and advanced-stage (T0-3N2-3M0; T4N0-3M0; TxNxM1) lung cancer although not statistically significant for all estimates. Among low-stage patients all-cause mortality was 15% higher in patients with short vs higher education, 26% higher for low vs high income and 23% higher for living alone vs living with a partner. In advanced-stage patients, differences in all-cause mortality was 11%, 14% and 8% for education, income and cohabitation status. Stage, treatment, Charlson Comorbidity Score and Performance Score attenuated associations but did not eliminate the association between low income (HR, 1.12; 95% CI, 1.05-1.19) and living alone (HR, 1.15; 95 CI, 1.06-1.25) in low stage lung cancer patients while no social differences in adjusted HR remained in advanced-stage patients. Conclusions: We show that even in a country with free and equal access to health care disparities exist in access to lung cancer treatment both of curative and of palliative intent. Differences in stage, treatment and presence of comorbidity by social position explained most of the social inequality in lung cancer survival although differences remained in the short term for low-stage patients.

P-371 Therapeutic compliance and its related factors in lung cancer patients

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S185
Author(s):  
Chi Young Jung ◽  
Si-Hyun Nam ◽  
Sin Kam ◽  
Min-Hae Yeh ◽  
Jae Yong Park
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Related Factors ◽  
Lung Cancer Patients

scholarly journals Lung cancer survival in Norway, 1997–2011: from nihilism to optimism

2015 ◽  
Vol 47 (1) ◽  
pp. 275-287 ◽  
Author(s):  
Yngvar Nilssen ◽  
Trond Eirik Strand ◽  
Lars Fjellbirkeland ◽  
Kristian Bartnes ◽  
Bjørn Møller
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Survival ◽  
Treatment Options ◽  
Diagnostic Testing ◽  
Relative Survival ◽  
Population Based ◽  
Related Factors ◽  
Lung Cancer Patients ◽  
Lung Cancer Survival

We examine changes in survival and patient-, tumour- and treatment-related factors among resected and nonresected lung cancer patients, and identify subgroups with the largest and smallest survival improvements.National population-based data from the Cancer Registry of Norway, Statistics Norway and the Norwegian Patient Register were linked for lung cancer patients diagnosed during 1997–2011. The 1- and 5-year relative survival were estimated, and Cox proportional hazard regression, adjusted for selected patient characteristics, was used to assess prognostic factors for survival in lung cancer patients overall and stratified by resection status.We identified 34 157 patients with lung cancer. The proportion of histological diagnoses accompanied by molecular genetics testing increased from 0% to 26%, while those accompanied by immunohistochemistry increased from 8% to 26%. The 1-year relative survival among nonresected and resected patients increased from 21.7% to 34.2% and 75.4% to 91.5%, respectively. The improved survival remained significant after adjustment for age, sex, stage and histology. The largest improvements in survival occurred among resected and adenocarcinoma patients, while patients ≥80 years experienced the smallest increase.Lung cancer survival has increased considerably in Norway. The explanation is probably multifactorial, including improved attitude towards diagnostic work-up and treatment, and more accurate diagnostic testing that allows for improved selection for resection and improved treatment options.

scholarly journals The Proportion of Latent Tuberculosis Infection in Naive Lung Cancer Patients at Persahabatan Hospital Jakarta

2019 ◽  
Vol 39 (4) ◽  
pp. 256-265
Author(s):  
Erlina Burhan ◽  
Ririen Razika Ramdhani ◽  
Jamal Zaini
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Close Contact ◽  
Cancer Prognosis ◽  
Related Factors ◽  
Cross Sectional ◽  
Lung Cancer Patients ◽  
Total Lymphocyte ◽  
Latent Tb ◽  
Latent Tb Infection

Background: Lung cancer and pulmonary tuberculosis (TB) are two major public health problems associated with significant morbidities and mortalities. The increased prevalence of active TB and latent TB reactivation in lung cancer patients and negative effect of pulmonary TB in lung cancer prognosis needed screening of lung cancer patients for latent TB infection (LTBI). This study aimed to determine the proportion of LTBI in lung cancer patients, their characteristics and the relationship between them. Methods: This study used cross-sectional design. Collecting sample used consecutive sampling of 86 newly diagnosed treatment-naive lung cancer patients from RSUP Persahabatan in 2015 to 2016. The presence of LTBI was determined by Quantiferon-TB Gold-In-Tube (QFT- GIT) after having Mycobacterium TB not detected result from Xpert MTB/RIF sputum test. Demographic characteristics and cancer-related factors associated with LTBI were investigated. Results: The results of latent TB tests were IGRA(+) 12.8%, IGRA(-) 68.6% and IGRA(I) 18.6%. Number of male patients with lung cancer with latent were 68.6%, as many as 55.8% were immunized with BCG, 4.6% had close contact with TB and 64% were using smoking. Most types of cancer were adenocarcinomas (77.9%) with advanced stage (82.6%) and general display status 2 (50%). The characteristics that show an association with IGRA results are the location of the cancer and the total lymphocyte count. Conclusion: The proportion of latent TB in lung cancer patients at the RSUP Persahabatan was 12.8%. The location of the cancer associated with the area of typical TB was related to latent TB, although it cannot be canceled. Results of IGRA(I) in lung cancer patients with low total lymphocyte counts prove IGRA sensitivity in the protection of latent TB infection in immunocompromised patients. (J Respir Indo. 2019; 39(4): 256-65)

Sign in / Sign up

Export Citation Format

Share Document